Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (Businesswire) - Mar 14, 2024 - "PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026."
P2b data • Lupus Nephritis
|